The objective of study GH101 is to take an integrative approach to the fields of pharmacogenomics, cancer genomics, mRNA microarrays and nutrigenomics. These disciplines have evolved from the original human genome project but have essentially remained discreet. The integration of these genetic disciplines into a computational model has the potential to increase diagnostic yield and provide a clearer genetic picture to determine actionable events to improve healthcare.
With the use of advanced technology, GH101 is designed to identify differentially expressed genes (DEGs) associated with development of chronic diseases such as CVD, ESRD, PTSD, and cancers.